Literature DB >> 393789

Pentoxifylline -- a biomedical profile.

R Müller.   

Abstract

The therapeutical benefit of pentoxifylline (Trental) in vascular disorders and chronic diseases which provoke disturbances in nutritive microcirculation is reviewed. With its hemorheological activity, pentoxifylline offers a new approach to ameliorate impaired blood flow in affected microvasculature. This statement is given evidence by numerous experimental and clinical data which demonstrate efficacy in various indications, wuch as cerebrovascular insufficiency, senile organic brain syndrome, transient ischemic attacks, cerebral infarctus, ocular and otological circulatory disorders, peripheral angiopathies of arteriosclerotic, diabetic, or inflammatory origin with intermittent claudication, leg ulcers and other disturbances. In vitro and in vivo findings disclose that the efficacy is based on hemorheological effects, such as improving local hyperviscosity, hyperaggregability of red cells or platelets, erythrocyte fluidity and hypercoagulability resulting in a better oxygenation of affected tissues.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 393789

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  12 in total

1.  Hepatosplanchnic and peripheral tissue oxygenation during treatment of hemorrhagic shock: the effects of pentoxifylline administration.

Authors:  A Nordin; L Mildh; H Mäkisalo; M Härkönen; K Höckerstedt
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

2.  The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells.

Authors:  S O Sowemimo-Coker; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Correction of a developmental defect in neutrophil activation and movement.

Authors:  H R Hill; N H Augustine; J A Newton; A O Shigeoka; E Morris; F Sacchi
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Authors:  Soumya Chatterjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

5.  The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.

Authors:  Jessie M Huisinga; Iraklis I Pipinos; Jason M Johanning; Nicholas Stergiou
Journal:  J Neuroeng Rehabil       Date:  2010-06-07       Impact factor: 4.262

6.  24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas.

Authors:  S Raptis; A Mitrakou; D Hadjidakis; E Diamantopoulos; C Anastasiou; A Fountas; R Müller
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

Review 7.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

8.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

9.  In vitro modulation of normal and diseased human neutrophil function by pentoxifylline.

Authors:  M A Boogaerts; S Malbrain; P Meeus; L van Hove; G E Verhoef
Journal:  Blut       Date:  1990 Aug-Sep

10.  The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse.

Authors:  P L Sensky; V E Prise; A E Ward; D G Hirst
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.